Adipotide

Περιγραφή

Adipotide, scientifically designated as prohibitin-targeting peptide 1 or FTPP (Fat-Targeted Proapoptotic Peptide), is a synthetic peptidomimetic with the sequence CKGGRAKDC-GG-D(KLAKLAK)₂. Developed as a novel approach to obesity treatment, Adipotide works by binding to prohibitin on the surface of endothelial cells in white adipose tissue vasculature, delivering a proapoptotic peptide payload (KLAKLAK)₂ that triggers programmed cell death specifically in the blood vessels supplying fat cells—leading to reduced blood flow, ischemia, and subsequent apoptosis of adipocytes without broadly affecting other tissues. Preclinical studies in obese rodent models demonstrated rapid and substantial weight loss (up to 30% body weight reduction in 28 days) primarily from fat mass, with preservation of lean mass, while obese rhesus monkeys treated with Adipotide showed marked decreases in body weight (around 11% in initial phases), significant reductions in abdominal circumference, improved insulin resistance (using ~50% less insulin post-treatment), and better metabolic profiles without severe toxicity at therapeutic doses. Early-phase human trials (Phase 1 initiated around 2011 by Arrowhead Research for safety assessment, initially in cancer contexts due to similar vascular targeting) explored its tolerability, but development for obesity stalled, and no large-scale Phase 2/3 trials for weight management have advanced to approval. As of 2026, Adipotide remains investigational and not FDA-approved for any therapeutic use, including obesity, weight loss, or metabolic disorders—available only through research channels or certain compounding sources for experimental purposes, with ongoing interest in targeted adipose therapeutics but no recent major breakthroughs shifting it to clinical availability. In research and biohacking discussions, it is often administered via subcutaneous injection (doses in studies scaled from animal data, typically microgram to low milligram ranges), with users reporting potential for selective fat reduction, especially visceral fat, alongside metabolic improvements. However, human data is extremely limited, and risks include potential off-target effects on other vascular beds, kidney function concerns (requiring monitoring), injection-site reactions, fatigue, or unknown long-term safety due to the proapoptotic mechanism. It is prohibited by WADA for athletes and should never be used without strict medical supervision from a qualified provider experienced in experimental peptides, as unregulated sources pose risks of impurity, incorrect dosing, serious adverse reactions, or legal issues. Prioritize evidence-based obesity management—diet, exercise, behavioral changes, and approved medications like GLP-1 agonists—over unapproved research compounds. Always consult a healthcare professional for personalized guidance, monitoring (including renal function), and to discuss approved alternatives rather than self-experimentation with Adipotide.

ALSO SEE